ADPT — Adaptive Biotechnologies Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1478320 ·
Last close
$21.06
Market Cap
$3.37B
52W High
$22.80
52W Low
$12.50
ADV30
3,496,773
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 70,874,000 | 52,166,000 | -19,206,000 | -20,033,000 | 505,943,000 | 77,581,000 | 281,702,000 |
| Dec 2025 | 71,681,000 | 53,457,000 | -12,773,000 | -13,579,000 | 512,736,000 | 70,495,000 | 287,735,000 |
| Sep 2025 | 93,973,000 | 75,816,000 | 10,290,000 | 9,546,000 | 490,610,000 | 55,034,000 | 286,357,000 |
| Jun 2025 | 58,879,000 | 40,880,000 | -25,036,000 | -25,614,000 | 496,637,000 | 43,163,000 | 317,101,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,986,000
Investing CF
$37,950,000
Financing CF
$30,403,000
CapEx
$-2,959,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,363,323,000
Inventory
$9,820,000
Receivables
$50,365,000
ST Investments
$156,485,000
EBIT TTM
$-47,679,000
Pretax Income TTM
$-59,457,000
Interest Exp TTM
$11,778,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$295,407,008
EBITDA
$-29,786,000
Free Cash Flow
$16,102,625
Enterprise Value
$3,486,715,648
Total Cash
$218,334,000
Total Debt
$208,180,992
Shares Out
160,044,392
Trailing EPS
$-0.32
Book Value
$1.35
ROE
-24.0%
ROA
-5.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,976,000 | -57,123,000 | -59,499,000 | 512,736,000 | 287,735,000 | — | -45,986,000 |
| Dec 2024 | 178,957,000 | -155,344,000 | -159,492,000 | 539,376,000 | 336,891,000 | — | -95,212,000 |
| Dec 2023 | 170,276,000 | -201,606,000 | -225,250,000 | 661,134,000 | 352,856,000 | — | -156,324,000 |
| Dec 2022 | 185,308,000 | -200,186,000 | -200,191,000 | 856,617,000 | 392,519,000 | — | -183,945,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | $3.36B | $32.68 | — |
| DNLI | Denali Therapeutics Inc. | $4.08B | $25.68 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.66B | $10.45 | — |
| RLAY | Relay Therapeutics, Inc. | $4.36B | $20.00 | — |
| KOD | Kodiak Sciences Inc. | $2.59B | $41.31 | — |
News headlines (Yahoo Finance, 1h cache)
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
2026-07-09 20:05 · Yahoo
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
2026-06-30 12:30 · Yahoo
Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Gr
2026-06-29 17:30 · Yahoo
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)
2026-06-27 22:13 · Yahoo
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
2026-06-17 10:00 · Yahoo
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
2026-06-15 20:10 · Yahoo
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
2026-06-15 20:05 · Yahoo
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
2026-06-14 22:46 · Yahoo
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
2026-06-12 09:44 · Yahoo
OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery
2026-06-09 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.